Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients

Launched by CHILDREN'S CANCER HOSPITAL EGYPT 57357 · Jul 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of laser therapy to help reduce a painful condition called oral mucositis in children who are being treated for a type of blood cancer known as acute lymphoblastic leukemia (ALL). Oral mucositis often occurs during chemotherapy and can cause significant discomfort. The researchers want to find out if two different types of lasers – one with a red light and the other with an infrared light – can help ease the pain and speed up healing for children experiencing this condition.

To be eligible for the study, children aged 3 to 14 who are currently receiving chemotherapy for ALL and have oral mucositis that is moderate to severe (grade 2 or higher) can participate. They will be randomly assigned to one of three groups: one group will receive treatment with the red laser, another with the infrared laser, and the third group will receive a similar procedure without any actual laser treatment (this is called a mock treatment). Throughout the study, the children will be monitored for pain and the healing of their mouth sores over an 11-day period. It's important to note that children who have had prior laser treatment, are receiving radiation therapy, or have certain serious health conditions will not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with Acute Lymphoblastic Leukemia in the induction therapy phase and have oral mucositis grade 2 or more.
• • 2. Age: 3-14 years old of both genders.
• • 3. No previous treatment with laser.
• • 4. Ability to open mouth for more than 2 cm for the duration of laser application with a level of cooperation (Frankl rating 3 or 4).
• • 5. Patients who still have 10 days in their induction therapy phase or can be followed up for a mininum of 10 days after the development of oral mucositis
• Exclusion Criteria:
• • 1. Patients receiving radiotherapy
• • 2. Received oral Cryotherapy or IV keratinocyte growth factor for oral mucositis
• • 3. Patients with unstable clinical condition (e.g. sepsis)
• • 4. Patients who will be withdrawn from participation according to their request or due to loss in follow up